The market is broken down by contaminant type including pathogens, genetically modified organisms (GMOs), toxins, residues and others. Of these, pathogen testing has the largest share of the market. Valued at nearly $1.8 billion in 2007, this segment is expected to be worth $2.4 billion by 2012, a CAGR of 5.1%.